SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house U.S. site to make the blockbuster ...

Merck CEO Robert Davis joins 'Mornings with Maria' to discuss the new $1 billion biologics manufacturing facility slated to ...